BACKGROUND: Classical Hodgkin's lymphoma is characterized by a minority of neoplastic cells surrounded by a heterogeneous background population of non-neoplastic cells including lymphoma-associated macrophages. High levels of expression of both the monocyte/macrophage lineage-associated antigens CD68 and CD163 have been suggested to have pro-tumor effects. The aim of our study was to correlate expression of CD68 and CD163 with the clinico-pathological features and prognosis of a cohort of patients with previously untreated Hodgkin's lymphoma. DESIGN AND METHODS: A tissue microarray was constructed from paraffin-embedded tumor tissues from 288 cases of classical Hodgkin's lymphoma. CD68 and CD163 expression was assessed immunohistochemically and the degree of macrophage infiltration within the tumor was scored using point grid counting. Clinical data were obtained from clinical records. RESULTS: The patients' median age was 37 years (range, 6-86 years). The male to female ratio was 1.2. In classical Hodgkin's lymphoma (n = 288) high CD68 and CD163 expression correlated, at the univariate level, with poorer overall survival (P=0.002 and P=0.03, respectively) and event-free survival (P=0.03 and P=0.04, respectively). At the multivariate level, high CD68 expression remained significantly predictive of overall survival (P=0.004). In addition, we demonstrated that both high CD68 and CD163 expression were associated with the presence of Epstein-Barr virus in the neoplastic cells (P=0.001 and P=0.0002, respectively). CONCLUSIONS: In classical Hodgkin's lymphoma, high expression of the macrophage/monocyte-related antigens CD68 and CD163 correlates with adverse outcome and with the presence of Epstein-Barr virus in the tumor cell population.
BACKGROUND:Classical Hodgkin's lymphoma is characterized by a minority of neoplastic cells surrounded by a heterogeneous background population of non-neoplastic cells including lymphoma-associated macrophages. High levels of expression of both the monocyte/macrophage lineage-associated antigens CD68 and CD163 have been suggested to have pro-tumor effects. The aim of our study was to correlate expression of CD68 and CD163 with the clinico-pathological features and prognosis of a cohort of patients with previously untreated Hodgkin's lymphoma. DESIGN AND METHODS: A tissue microarray was constructed from paraffin-embedded tumor tissues from 288 cases of classical Hodgkin's lymphoma. CD68 and CD163 expression was assessed immunohistochemically and the degree of macrophage infiltration within the tumor was scored using point grid counting. Clinical data were obtained from clinical records. RESULTS: The patients' median age was 37 years (range, 6-86 years). The male to female ratio was 1.2. In classical Hodgkin's lymphoma (n = 288) high CD68 and CD163 expression correlated, at the univariate level, with poorer overall survival (P=0.002 and P=0.03, respectively) and event-free survival (P=0.03 and P=0.04, respectively). At the multivariate level, high CD68 expression remained significantly predictive of overall survival (P=0.004). In addition, we demonstrated that both high CD68 and CD163 expression were associated with the presence of Epstein-Barr virus in the neoplastic cells (P=0.001 and P=0.0002, respectively). CONCLUSIONS: In classical Hodgkin's lymphoma, high expression of the macrophage/monocyte-related antigens CD68 and CD163 correlates with adverse outcome and with the presence of Epstein-Barr virus in the tumor cell population.
Authors: Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne Journal: N Engl J Med Date: 2010-03-11 Impact factor: 91.245
Authors: Bruno Chetaille; François Bertucci; Pascal Finetti; Benjamin Esterni; Aspasia Stamatoullas; Jean Michel Picquenot; Marie Christine Copin; Frank Morschhauser; Olivier Casasnovas; Tony Petrella; Thierry Molina; Anne Vekhoff; Pierre Feugier; Reda Bouabdallah; Daniel Birnbaum; Daniel Olive; Luc Xerri Journal: Blood Date: 2008-12-18 Impact factor: 22.113
Authors: Karl R N Baumforth; Anna Birgersdotter; Gary M Reynolds; Wenbin Wei; Georgia Kapatai; Joanne R Flavell; Emma Kalk; Karen Piper; Steve Lee; Lee Machado; Kerry Hadley; Anne Sundblad; Jan Sjoberg; Magnus Bjorkholm; Anna A Porwit; Lee-Fah Yap; Soohwang Teo; Richard G Grundy; Lawrence S Young; Ingemar Ernberg; Ciaran B J Woodman; Paul G Murray Journal: Am J Pathol Date: 2008-05-23 Impact factor: 4.307
Authors: Cheng-Han Lee; Inigo Espinosa; Suzan Vrijaldenhoven; Subbaya Subramanian; Kelli D Montgomery; Shirley Zhu; Robert J Marinelli; Johannes L Peterse; Neal Poulin; Torsten O Nielsen; Rob B West; C Blake Gilks; Matt van de Rijn Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia Journal: Haematologica Date: 2012-02-07 Impact factor: 9.941
Authors: Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor Journal: Cancer Res Date: 2012-06-22 Impact factor: 12.701
Authors: Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti Journal: Leuk Lymphoma Date: 2013-04-11
Authors: Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig Journal: Clin Cancer Res Date: 2013-05-14 Impact factor: 12.531